网站地图 加入收藏 中文 English
 
首页 中心概况 组织机构 研究队伍 科学研究 人才培养 交流合作 支撑服务 人才招聘 下载专区 联系我们
当前位置:首页 - 研究队伍
黄晓军

黄晓军

 

电子邮件: xjhrm(at)medmail(dot)com(dot)cn;
电话: +86-10-88326006;
传真:
+86-10-88324577;

 

研究方向:
主要从事造血干细胞移植和恶性血液病的应用基础和临床研究,总体思路是:以解决血液病临床重大问题为导向,结合实验室机制研究及生物学标记技术,形成具有可操作性的诊疗体系。目前采用“临床病例模型—体外实验及动物模型—完善临床体系”的研究模式,系统性地研究(1)单倍型造血干细胞移植及免疫机制;(2)基于分子标记的血液病分层、个性化诊疗体系;(3)造血干细胞、白血病干细胞与微环境相互作用机制。

 

代表性科研论文:

1.      Zhu HH, Qin YZ, Huang XJ*. Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med. 2014;370(19):1864-1866.
2.      Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, Liu YR, Zhu HH, Chen J, Dai M, Huang XJ*. RUNX1/RUNX1T1-based MRD-monitoring early after allogeneic transplantation rather than c-KIT mutations in adult t(8;21) AML allows further risk stratification. Blood. 2014. pii: blood-2014-03-563403. [Epub]
3.      Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Yan CH, Huo MR, Li D, Huang XJ*. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843-850.
4.      Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, Jiang Q, Xu LP, Lu J, Han W, Bao L, Wang Y, Chen YH, Wang JZ, Wang FR, Lai YY, Chai JY, Wang LR, Liu YR, Liu KY, Jiang B, Huang XJ*. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056-4062.
5.      Huang XJ*, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, Jiang B, Jiang Q, Jiang H, Chen YH, Chen H, Han W, Liu KY, Wang Y. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood. 2012;119(23):5584-5590.
6.      Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ*. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(14):3256-3262.
7.      Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ*. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011;117(11):3032-3040.
8.      Xiao-Jun H*, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C, Yu-Hong C, Wei H, Jing-Zhi W, Yao C, Xiao-Hui Z, Hong-Xia S, Feng-Rong W, Fei-Fei T. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res. 2009;15(14):4777-4783.
9.      Zhao XY, Lv M, Xu LL, Qian X, Huang XJ*. Donor Th17 cells and IL-21 may contribute to the development of chronic graft-versus-host disease after allogeneic transplantation. Eur J Immunol. 2013;43(3):838-850.
10.   Zhao XY, Chang YJ, Xu LP, Zhang XH, Liu KY, Li D, Huang XJ*. HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients. Br J Cancer. 2014. doi: 10.1038/bjc.2014.423. [Epub]

 

 

 

版权所有 生命科学联合中心